Pangenomic Health Inc.
NARA
CNSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -4.84% | -1.52% | |||
| Gross Profit | 4.84% | 1.52% | |||
| SG&A Expenses | -24.91% | -0.63% | |||
| Depreciation & Amortization | -34.78% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.85% | 16.42% | |||
| Operating Income | 22.85% | -16.42% | |||
| Income Before Tax | 92.20% | -1,044.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 92.20% | -1,044.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 92.20% | -1,044.61% | |||
| EBIT | 22.85% | -16.42% | |||
| EBITDA | 22.74% | -16.69% | |||
| EPS Basic | 93.19% | -329.50% | |||
| Normalized Basic EPS | 33.64% | 55.69% | |||
| EPS Diluted | 93.19% | -329.50% | |||
| Normalized Diluted EPS | 33.64% | 55.69% | |||
| Average Basic Shares Outstanding | 14.36% | 166.57% | |||
| Average Diluted Shares Outstanding | 14.36% | 166.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||